FDA Launches Expedited IND Pilot to Accelerate Clinical Development

<p>On September 15, 2026, the U.S. Food and Drug Administration (FDA) announced the launch of an Expedited Investigational New Drug (IND) pilot program. This pilot is designed to accelerate clinical development timelines by providing a faster track for certain IND applications.</p><p>The FDA has begun accepting applications under this program, sign...

Published date: 23-09-2026 10:03 AM

Source:

On September 15, 2026, the U.S. Food and Drug Administration (FDA) announced the launch of an Expedited Investigational New Drug (IND) pilot program. This pilot is designed to accelerate clinical development timelines by providing a faster track for certain IND applications.

The FDA has begun accepting applications under this program, signaling a confirmed change in regulatory procedures. This initiative is anticipated to impact clinical investigators, sponsors, and institutional review boards by offering more efficient review processes.

The Expedited IND pilot reflects the FDA’s commitment to improving the drug development process, potentially allowing for quicker access to innovative therapies while maintaining rigorous safety standards.

The U.S. Food and Drug Administration (FDA) has initiated a new pilot program to expedite the Investigational New Drug (IND) application process. This effort aims to streamline the pathway for clinical development and speed up regulatory review.

View Comments (0)

Want to join the conversation?

Already a member? Login New to JobsReach Healthcare? Sign up